Journal article

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

Anna K Nowak, Chris Brown, Michael J Millward, Jenette Creaney, Michael J Byrne, Brett Hughes, Gabriel Kremmidiotis, David C Bibby, Annabell F Leske, Paul LR Mitchell, Nick Pavlakis, Michael Boyer, Martin R Stockler

Lung Cancer | ELSEVIER IRELAND LTD | Published : 2013

DOI: 10.1016/j.lungcan.2013.05.006

University of Melbourne Researchers

Grants

Funding Acknowledgements

The study was funded by Bionomics Ltd.

Citation metrics

39Web of Science
40Scopus

Keywords

Phosphate
Humans
Tumor Vasculature
Lung Neoplasms
Science & Technology
Cancer
Treatment Outcome
Male
Plus Bevacizumab
Tubulin Modulators
2nd-Line Therapy
Phase Ii
Respiratory System
Benzofurans
Antineoplastic Agents
Oncology
Vascular Disrupting Agent
Sunitinib
Female
Biomarkers
Organophosphates
Inhibitor
Previously Treated Patients
Gpi-Linked Proteins
Radiography
Mesothelioma
Tumor Burden
Life Sciences & Biomedicine
Middle Aged
Aged, 80 and Over
Endothelial Growth-Factor
Schedule
Clinical Trial
Neoplasm Staging
Adult
Bnc105p
Aged
Pleural Neoplasms